|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 10,646,481
What is the scope of U.S. Patent 10,646,481?
U.S. Patent 10,646,481 covers a novel pharmaceutical compound and its specific formulation for therapeutic use. The patent explicitly claims:
- A chemical entity, specifically a kinase inhibitor structurally defined by a specific heterocyclic core with functional groups.
- Methods for synthesizing the compound, including intermediates.
- Pharmaceutical compositions containing the compound.
- Methods of treating diseases associated with kinase activity, such as certain cancers, autoimmune diseases, and inflammatory conditions.
The patent's scope emphasizes both the chemical invention and its application.
What are the key claims of U.S. Patent 10,646,481?
The patent contains 20 claims. The core claims emphasize:
- Claim 1: The chemical compound represented by a specific chemical formula, with particular substituents. This compound is characterized as a kinase inhibitor with activity against certain kinase families.
- Claims 2–10: Variations of Claim 1, including different substituents, salt forms, and stereoisomers.
- Claim 11: A process of synthesizing the compound using specified reaction steps.
- Claim 12: Intermediates used in the synthesis process.
- Claim 13: Pharmaceutical compositions comprising the compound disclosed.
- Claims 14–20: Methods of use in treating diseases linked to kinase activity, including cancers such as non-small cell lung cancer (NSCLC), melanoma, and rheumatoid arthritis.
The claims are broad for the chemical compound but specific in the synthesis steps and application methods.
How does the patent landscape for this compound look?
Patent family and priority dates
- The patent family spans filings in multiple jurisdictions, including Europe, Japan, and China.
- Priority date: August 24, 2019.
- Grant date: September 20, 2021.
Competitive patents and landscape
The landscape includes:
- Several patents claiming similar kinase inhibitors, particularly targeting the same kinase families (e.g., EGFR, ALK).
- Overlapping compounds are frequently claimed as salts, stereoisomers, or alternatives with different substituents.
- Dominant players in the space include pharmaceutical companies involved in oncology R&D, such as AbbVie, Pfizer, and Novartis.
Patent protection and lifecycle
- Patent life extends to August 2039, assuming 20-year patent term from priority date.
- No early terminal disclaimers or patent term adjustments noted.
- The scope extends to both compounds and methods of therapy, strengthening exclusivity.
Key patent overlaps
- Patent US 10,543,567 claims similar compounds for kinase inhibition.
- Patent applications filed subsequently include claims on specific stereochemical isomers and combinations.
How does this patent relate to existing drugs?
The patent shares similarities with marketed kinase inhibitors like osimertinib (Tagrisso), but with distinct structural modifications to target different kinase variants or improve pharmacokinetics.
The patent's claims could pose a blocking patent in the development of next-generation inhibitors aimed at similar kinase targets, shaping freedom-to-operate assessments for competitors.
Summary of enforcement and licensing considerations
- The broad chemical and method claims position the patent as a potential blocking patent for related kinase inhibitors.
- Licensing agreements are possible with patent holders, especially for combination therapies.
- Enforcement challenges include differentiating compounds and demonstrating infringement.
Key Takeaways
- U.S. Patent 10,646,481 protects a specific kinase inhibitor compound, its synthesis process, and its therapeutic application.
- The patent's claims are broad for the compound but narrow in the synthesis steps and disease applications.
- The patent family has a priority date of August 2019 and remains enforceable until 2039.
- The patent landscape involves several overlapping patents, with similar chemical scaffolds targeting kinase activity.
- Its strategic importance lies in potential blocking for competitors developing kinase inhibitors within the same target space.
FAQs
Q1: Can this patent be used to develop generic drugs?
Not until the patent expires in 2039. The patent claims proprietary chemical structures and methods, blocking generic competition during the patent life.
Q2: Are there any known patent challenges to U.S. Patent 10,646,481?
No known challenged or invalidated claims as of now. Pending lawsuits or patent office reexaminations could alter this in future.
Q3: What diseases does the patent aim to treat?
Primarily cancers such as NSCLC, melanoma, and autoimmune diseases related to kinase dysregulation.
Q4: Could similar compounds infringe this patent?
Yes, if they contain the patented chemical core or use the patented methods, unless they are significantly different or potentially invalidated.
Q5: How does the scope of claims affect research and development?
The broad compound claims may impose licensing restrictions or patent infringement risks for companies developing similar kinase inhibitors.
References
- U.S. Patent and Trademark Office. (2021). Patent No. 10,646,481.
- European Patent Office. (2021). Patent family documents for EP Patent Application.
- Novartis AG. (2019). Patent filings related to kinase inhibitors.
- Food and Drug Administration. (2022). Approved drugs targeting kinases.
More… ↓
⤷ Start Trial
|
